- Home
- NYXH vs KOD Comparison
NYXH vs KOD Comparison
Compare NYXH & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NYXH
- KOD
- Stock Information
- Founded
- NYXH 2009
- KOD 2009
- Country
- NYXH Belgium
- KOD United States
- Employees
- NYXH N/A
- KOD N/A
- Industry
- NYXH Medical/Dental Instruments
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NYXH Health Care
- KOD Health Care
- Exchange
- NYXH Nasdaq
- KOD Nasdaq
- Market Cap
- NYXH 179.1M
- KOD 198.4M
- IPO Year
- NYXH 2021
- KOD 2018
- Fundamental
- Price
- NYXH $4.78
- KOD $9.84
- Analyst Decision
- NYXH Strong Buy
- KOD Hold
- Analyst Count
- NYXH 3
- KOD 4
- Target Price
- NYXH $15.00
- KOD $11.75
- AVG Volume (30 Days)
- NYXH 60.4K
- KOD 443.4K
- Earning Date
- NYXH 11-05-2025
- KOD 11-13-2025
- Dividend Yield
- NYXH N/A
- KOD N/A
- EPS Growth
- NYXH N/A
- KOD N/A
- EPS
- NYXH N/A
- KOD N/A
- Revenue
- NYXH $5,793,306.00
- KOD N/A
- Revenue This Year
- NYXH $118.20
- KOD N/A
- Revenue Next Year
- NYXH $278.04
- KOD N/A
- P/E Ratio
- NYXH N/A
- KOD N/A
- Revenue Growth
- NYXH 2.94
- KOD N/A
- 52 Week Low
- NYXH $4.56
- KOD $1.92
- 52 Week High
- NYXH $11.87
- KOD $11.60
- Technical
- Relative Strength Index (RSI)
- NYXH 26.11
- KOD 56.74
- Support Level
- NYXH $4.56
- KOD $9.10
- Resistance Level
- NYXH $6.09
- KOD $9.93
- Average True Range (ATR)
- NYXH 0.26
- KOD 0.74
- MACD
- NYXH -0.08
- KOD -0.11
- Stochastic Oscillator
- NYXH 12.22
- KOD 66.52
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.